Furthermore, we are focusing on executing successful launches of both Monjuvi and Pemazyre, and we expect Tabrecta royalties to increase following the approvals and subsequent launches by Novartis in both the U.S. and Japan.
Utilize the input text as a context reference, choose the right relationship between 'Tabrecta' and 'Novartis' from the options.
Options: manufacturer, owner of, operator, location of formation